Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.

Antiviral therapy - 1 Jan 2009

Maïga Almoustapha-Issiaka, Malet Isabelle, Soulie Cathia, Derache Anne, Koita Victoria, Amellal Bahia, Tchertanov Luba, Delelis Olivier, Morand-Joubert Laurence, Mouscadet Jean-François, Murphy Robert, Cissé Mamadou, Katlama Christine, Calvez Vincent, Marcelin Anne-Genevieve

Abstract excerpt

BACKGROUND: HIV type-1 (HIV-1) integrase (IN) inhibitor resistance is the consequence of mutations that are selected in the viral IN gene targeted by antiretroviral drugs, such as raltegravir (RAL) and elvitegravir (EVG). The genetic barrier, defined as the number of viral mutations required to o...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Viral
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Integrase

Share to HIV Integrase Inhibitors

Share to Pyrrolidinones

Share to Quinolones

Share to Raltegravir Potassium

Source

Identifiers

PMID: 19320246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19320246-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.PMID 19320246Read ↗

Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B.Semantic proximity Read ↗

Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.Semantic proximity Read ↗

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.Semantic proximity Read ↗

Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil.Semantic proximity Read ↗

The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.Semantic proximity Read ↗

Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades.Semantic proximity Read ↗

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.Semantic proximity Read ↗

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.Semantic proximity Read ↗

Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes.Semantic proximity Read ↗

Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.Semantic proximity Read ↗

Resistance to Integrase InhibitorsSemantic proximity Read ↗

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.